Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Uterine Cervical Neoplasms 1Sarcoma 1Kidney Neoplasms 1Endocrine Gland Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Gemcitabine 5Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4selpercatinib 2niraparib 2napabucasin 2entinostat 2Ocoxin 2Irinotecan 2Bevacizumab 2temsirolimus 1tariquidar 1repotrectinib 1pralsetinib 1pembrolizumab 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1ganitumab 1copper dotatate CU-64 1Valproic Acid 1Trabectedin 1Therapeutic Irrigation 1Taxes 1Sunitinib 1Staining and Labeling 1Sirolimus 1Psilocybin 1Phlebotomy 1Paclitaxel 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endocrine Gland Neoplasms × tariquidar × Clear all
NCT00071058 2012-09-18

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
50 enrolled 10 charts

Adrenal Cortex Neoplasms, Endocrine Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡